Login

If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.

26th February, 2021

Respiratory Symptoms Questionnaire manuscript published

Home > News > Respiratory Symptoms Questionnaire manuscript published

We are pleased to announce that ‘Validation of a diagnosis-agnostic symptom questionnaire for asthma and/or COPD’ has been published in ERJ Open Research.1

The article, authored by members of the NOVELTY Scientific Community and the AstraZeneca team, examines the reliability and validity of the novel Respiratory Symptoms Questionnaire (RSQ) in patients with asthma and/or COPD in the NOVELTY study.

Questionnaires that are used to assess respiratory symptoms have been designed specifically for patients with a confirmed diagnosis of either asthma or COPD. There is a lack of questionnaires that can be used in both patients with asthma and patients with COPD, and that also account for the well-recognised overlap between the two conditions. The RSQ was developed as a simple four-item, patient-reported, diagnosis-agnostic tool to assess the frequency of respiratory symptoms and their impact on activity. The first question of the RSQ asks how often people have experienced respiratory symptoms during the day, while subsequent questions ask about the impact of the respiratory symptoms: how often have they used a quick relief inhaler; how limited have their activities been; and how often have they woken up at night?

Baseline data were randomly sampled from patients who completed the RSQ in the NOVELTY study. Validation analysis of these data showed that the RSQ is a valid patient-reported tool for assessing respiratory symptoms in patients with physician-assigned asthma and/or COPD, and is a suitable alternative to employing different questionnaires for each diagnosis. The RSQ can be used for monitoring respiratory symptoms in clinical practice, clinical trials and real-world studies, and is a valuable diagnosis-agnostic tool for future analyses from the NOVELTY study. Future longitudinal data are required to further explore the performance of the RSQ, particularly with respect to assessing predictive validity and whether it reflects changes in respiratory symptoms over time.

The full article is available here.

Read a summary of this article, and other NOVELTY publications and presentations, here.

 

19 PARTICIPATING COUNTRIESa
~12,000 ENROLLED PATIENTSa
84% OF PATIENTS HAVE SPIROMETRY DATAb

You are now leaving: http://aznoveltyproject.com/

By following this link you will be leaving the NOVELTY study website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to NOVELTY study